Twenty-four-hour intraocular pressure control with omidenepag isopropyl 0.002% in patients with glaucoma and ocular hypertension

Shiratori N., Nishio Y., Takeda A., Sugimoto S., Takazawa K., Otsuka N., Ishida N., Shii D., Hori K., Nakamoto K.

2021
Clinical Ophthalmology

View publication

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

Department of Ophthalmology, Nippon Medical School, Tokyo, Japan; Shinanozaka Clinic, Tokyo, Japan; Japan Medical Affairs Group, Santen Pharmaceutical Co. Ltd., Osaka, Japan

Related Publications

Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.

Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.

The Development of a SIBS Shunt to Treat Glaucoma

Pinchuk L.

View all Glaucoma publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022